Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003013777 | SCV003307254 | pathogenic | Multiple endocrine neoplasia, type 1 | 2022-02-09 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant has not been reported in the literature in individuals affected with MEN1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asp136Glufs*49) in the MEN1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MEN1 are known to be pathogenic (PMID: 12112656, 17853334). For these reasons, this variant has been classified as Pathogenic. |
Mayo Clinic Laboratories, |
RCV004790315 | SCV005413993 | pathogenic | not provided | 2024-08-29 | criteria provided, single submitter | clinical testing | PP4, PM2, PVS1 |